Home » NIH Launches Trial of Remdesivir with Merck’s Rebif for COVID-19
NIH Launches Trial of Remdesivir with Merck’s Rebif for COVID-19
The NIH’s National Institutes of Allergy and Infectious Diseases (NIAID) has launched a phase 3 trial of Gilead Sciences’ remdesivir with Merck’s anti-inflammatory drug Rebif (interferon-beta-1a) for the treatment of hospitalized COVID-19 patients.
The trial will evaluate whether the combination treatment will reduce the recovery time compared to treatment with remdesivir alone. It will enroll more than 1,000 participants who will either receive the antiviral combination or a placebo with remdesivir.
The study is part of the NIAID’s Adaptive COVID-19 Treatment Trial (ACTT), which is designed to assess the safety and efficacy of novel therapeutics.
Upcoming Events
-
07May
-
14May
-
30May